Fundraising Fox
/Companies
Sign in

Intact Therapeutics

YC W19

San Francisco, US · Founded 2015 · 4 employees · 5 known investors

Find your way into Intact Therapeutics

Sign up to see every warm intro you have to Intact Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Intact Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Intact Therapeutics develops next-generation biopharmaceutical therapies for gastrointestinal diseases to address unmet clinical needs. The company is clinical-stage and focused on improving patient outcomes through innovative medicines.

BiotechHealthtechDrug DeliveryTherapeuticsUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (W19)

Intact Therapeutics was founded in 2015 by Ravi Pamnani and Sidhartha Sinha.

RPRavi Pamnani
Ravi PamnaniCEO & Co-FounderFounder and CEO of Intact Therapeutics, a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases.
SSSidhartha Sinha
Sidhartha SinhaFounder
NK
Navdeep KaurDirector of R\u0026D

Investors · 5

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Hanmi Healthcarereported

How we know: Y Combinator's founder network · Not right? Tell us

Stanford UniversityreportedStanford

How we know: Y Combinator's founder network · Not right? Tell us

Venture Investment AssociatesreportedPeapack

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 9

Intracellular TherapiesA biopharmaceutical company developing treatments for psychiatric and neurologic disorders based on research into how therapies affect cellular mechanisms. The company, now part of Johnson & Johnson, focuses on innovative therapies for patients with complex brain-related diseases.
Encepheal TherapeuticsEncepHeal develops small-molecule medications targeting the dopamine transporter to treat stimulant addiction, including cocaine and methamphetamine, for which no FDA-approved treatments currently exist. The company uses allosteric modulators designed to reduce drug cravings without the addictive potential of earlier dopamine-targeting approaches.
Iterion TherapeuticsIterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway. Its lead candidate is in clinical trials for advanced hepatocellular carcinoma and other Wnt-driven tumors such as colorectal cancer.
DelineateDelineate builds AI agents that help pharmaceutical companies design clinical trials more quickly by converting existing trial research into specialized datasets, reducing the time scientists spend on trial preparation.
CurebaseCurebase provides a software platform for clinical trial management, serving contract research coordinators and trial sites. The platform emphasizes modern technology, data integrity, and compliance for advancing medical research.
Mark Cuban Cost Plus Drug Company, PBCMark Cuban Cost Plus Drug Company manufactures affordable generic medications, offering lower-priced alternatives to existing pharmaceutical products.
NanograbNanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.
Entact BioEntact is a drug discovery company developing treatments for patients. It works in the biotechnology and therapeutics sector.
Incyte CorporationIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.

Companies working in the same space as Intact Therapeutics.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$296.5K
National Science FoundationPhase I2020$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Legal entities · 1

corporate structure
Intact Therapeutics, Inc.

Frequently asked questions

What does Intact Therapeutics do?
Intact Therapeutics develops next-generation biopharmaceutical therapies for gastrointestinal diseases to address unmet clinical needs. The company is clinical-stage and focused on improving patient outcomes through innovative medicines.
Who founded Intact Therapeutics?
Intact Therapeutics was founded by Ravi Pamnani, Sidhartha Sinha in 2015.
Who are Intact Therapeutics's investors?
Intact Therapeutics's investors include Brightstone Venture Capital, Y Combinator, Hanmi Healthcare, Stanford University, Venture Investment Associates.
Where is Intact Therapeutics headquartered?
Intact Therapeutics is headquartered in San Francisco, US.